|
Type of therapy
|
2009 (%)
|
2013 (%)
|
|---|
|
Lifestyle modification only
|
15.7
|
10.2
|
|
Oral anti-diabetic drug only
|
83.7
|
86.3
|
|
Insulin only
|
0.2
|
0.5
|
|
Oral anti-diabetic drug + insulin
|
0.5
|
3.0
|
|
Anti-diabetic drugs
|
|
Metformin
|
71.1
|
80.4
|
|
Sulphonylurea
|
57.0
|
60.4
|
|
Gliptin
|
0.0
|
1.2
|
|
Insulin
|
0.6
|
3.5
|
|
Others
|
0.1
|
0.1
|
|
Anti-hypertensive drugsa
|
|
None
|
2.5
|
3.6
|
|
ACEI or ARB
|
59.4
|
58.3
|
|
β-blocker
|
39.2
|
35.5
|
|
CCB
|
73.9
|
71.0
|
|
Diuretic
|
11.8
|
10.7
|
|
Other anti-hypertensive drugs
|
15.1
|
13.8
|
|
Lipid lowering drugs
|
|
Statin
|
9.0 (15.8 %)b
|
55.0 (56.9 %)b
|
|
Fibrate
|
4.6
|
2.5
|
|
Aspirin
|
8.8 (75.8 %)c
|
14.0 (75.7 %)c
|
- Others included Acarbose, Glucagon-like peptide-1 agonist, Meglitinides
-
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker
-
aThe denominator was diabetic patients with hypertension (93,234 and 106,361 at 2009 and 2013, respectively)
-
bThe bracket shows the proportion of diabetic patients with hyperlipidemia who are put on statin
-
cThe bracket shows the proportion of diabetic patients with confirmed CVD who were put on aspirin
